ArticleObesity pillars2026
Patient preferences for pharmacological treatments for obesity: The VOICE study.
Article in Obesity pillars, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the emergence of new pharmacological treatments for obesity, understanding patient preferences for different medication attributes is important for shared decision-making conversations. The purpose of this study was to evaluate preferences for specific obesity medication (OM) attributes. Methods: This was a cross-sectional online survey study. Adults living with Class I/II obesity or overweight with a comorbidity were recruited to complete a discrete choice experiment (DCE) and questions on willingness to inject OMs. The DCE included attributes for mode/frequency of administration, food/water restrictions, and storage requirements. A mixed logit model was used to calculate the relative attribute importance (RAI). Results: A total of 351 participants completed the study. When asked about their willingness to inject OMs, 25.4% of participants were unwilling to use weekly injections, and 17.7% were unwilling to use monthly injections. Mode/frequency of administration was the most important characteristic (RAI: 62.7%), followed by food/water restrictions (RAI: 21.2%), and storage (RAI: 16.1%). In the context of a treatment choice where weight loss and side effects were explicitly defined as equal across the options presented, a once-daily pill was significantly more preferred to a once-weekly injection (p < 0.001). Conclusions: Approximately one in four participants were unwilling to take a weekly injectable OM and significantly preferred daily oral medication. These results suggest opportunities to better align treatment attributes with patient preferences and the need to consider all aspects of OMs beyond efficacy and safety during shared decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.